Literature DB >> 7552372

Dipyridamole attenuates the development of iminodipropionitrile-induced dyskinetic abnormalities in rats.

M Tariq1, S al-Deeb, K al-Moutaery, G W Bruyn, D A Evans, M Arshaduddin.   

Abstract

The present investigation was undertaken to study the effect of dipyridamole on experimental dyskinesia in rats. The movement disorders were produced by intraperitoneal administration of iminodipropionitrile (IDPN) in the dose of 100 mg/kg per day for 12 days. Dipyridamole was administered orally, daily 30 min before IDPN in the doses of 0.5 g/kg, 1 g/kg, and 1.5 g/kg bodyweight in three different groups of rats. Twenty-four hours after the last dose of IDPN, animals were observed for neurobehavioral changes including vertical and horizontal head weaving, circling, backwalking, grip strength, and righting reflex. Immediately after behavioral studies brain specimens were collected for analysis of vitamin E, conjugated dienes, and lipid hydroperoxides as indices of oxygen-derived free radical (OFR) production. Our results showed that concurrent use of dipyridamole significantly protected rats against IDPN-induced neurobehavioral changes in a dose-dependent manner. Treatment of rats with dipyridamole inhibited IDPN-induced decrease of vitamin E and increase in conjugated dienes and lipid hydroperoxides in brain. These findings suggest the involvement of OFR in dipyridamole induced protection against the development of IDPN dyskinesia. Further studies are warranted to determine the role of dipyridamole as a prophylactic agent against the drug induced dyskinetic abnormalities.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7552372     DOI: 10.1016/0361-9230(95)00068-p

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  1 in total

1.  Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.

Authors:  Ikwunga Wonodi; Hirekatur V Gopinath; Judy Liu; Helene Adami; L Elliot Hong; Robert Allen-Emerson; Robert P McMahon; Gunvant K Thaker
Journal:  Psychopharmacology (Berl)       Date:  2011-05-03       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.